CD20 binding molecules
US8153125B2 · kind B2 · utility
7Cited by
1References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 20, 2004 |
| Grant date | Apr 10, 2012 |
| Priority date | — |
| Expiry date | Apr 16, 2026 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to CD20 binding molecules and nucleic acid sequences encoding CD20 binding molecules. In particular, the present invention relates to CD20 binding molecules with a high binding affinity, and a low dissociation rate, with regard to human CD20. Preferably, the CD20 binding molecules of the present invention comprise light and/or heavy chain variable regions with fully human frameworks (e.g. human germline frameworks).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.